Insight 2

A Phase II single-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior 1st to 3rd generation EGFR-tyrosine kinase inhibitor therapy.

MET

aktiv

2

Pius-Hospital Oldenburg

Georgstraße 12
26121 Oldenburg

Tel: 0441 / 229 0
Fax: 0441 / 229 1607
Frank.Griesinger@Pius-Hospital.de
www.pius-hospital.de/kontakt

Professor Dr. med. Frank Griesinger
Pius-Hospital Oldenburg
Klinik für Hämatologie und Onkologie
Universitätsklinik Innere Medizin-Onkologie
Medizinischer Campus Universität Oldenburg

Vorherige Studie
Nächste Studie
to top icon